July 2014 - 1st Time Decisions Not to Recommend (Word 68KB)
... Program) Authority Required (STREAMLINED) listing for sofosbuvir for the treatment of chronic hepatitis C on the basis of unacceptably high and likely underestimated costeffectiveness and the high and likely underestimated budgetary impact on the PBS. The PBAC recognised that treatment of hepatitis ...
... Program) Authority Required (STREAMLINED) listing for sofosbuvir for the treatment of chronic hepatitis C on the basis of unacceptably high and likely underestimated costeffectiveness and the high and likely underestimated budgetary impact on the PBS. The PBAC recognised that treatment of hepatitis ...
Prescribing Information
... Warnings and Precautions (5.4), and Drug Interactions (7.1)]. The appearance of hypotension after the initial dose of QBRELIS does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. ...
... Warnings and Precautions (5.4), and Drug Interactions (7.1)]. The appearance of hypotension after the initial dose of QBRELIS does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. ...
full Prescribing Information
... contribute to hypotension [see Warnings and Precautions (5.4), and Drug Interactions (7.1)]. The appearance of hypotension after the initial dose of QBRELIS does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. ...
... contribute to hypotension [see Warnings and Precautions (5.4), and Drug Interactions (7.1)]. The appearance of hypotension after the initial dose of QBRELIS does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. ...
BER02-021 BETASERON PI
... major classes of interferons have been identified: alfa, beta, and gamma. Interferon beta-1b, interferon alfa, and interferon gamma have overlapping yet distinct biologic activities.1-5 The activities of Interferon beta-1b are species-restricted and, therefore, the most pertinent pharmacologic infor ...
... major classes of interferons have been identified: alfa, beta, and gamma. Interferon beta-1b, interferon alfa, and interferon gamma have overlapping yet distinct biologic activities.1-5 The activities of Interferon beta-1b are species-restricted and, therefore, the most pertinent pharmacologic infor ...
University of Groningen Merits and demerits of the converting
... the renal vasculature,often in combination with a suppressedRAS. It is therefore no surprise that thesecategoriesof patients with EH showeda different renal responseto captopril. No conclusiveanswer can be supplied as to whether changesin renal function contributeto the hypotensiveaction of the drug ...
... the renal vasculature,often in combination with a suppressedRAS. It is therefore no surprise that thesecategoriesof patients with EH showeda different renal responseto captopril. No conclusiveanswer can be supplied as to whether changesin renal function contributeto the hypotensiveaction of the drug ...
Recent developments on the detection of harms arising from the use
... been seized. α-PVP is sold as a ‘research chemical’ online and is available in wholesale and consumer amounts. • 140 serious adverse events associated with α-PVP have been reported by 9 MS. This includes acute intoxications requiring hospitalisation and more than 100 deaths; in at least 23 of these ...
... been seized. α-PVP is sold as a ‘research chemical’ online and is available in wholesale and consumer amounts. • 140 serious adverse events associated with α-PVP have been reported by 9 MS. This includes acute intoxications requiring hospitalisation and more than 100 deaths; in at least 23 of these ...
Suggestion from clinicians
... We could not pool data, but third tier evidence in individual studies indicated similar efficacy to other active interventions (gabapentin, morphine, chlorimipramine, and amitriptyline), and to placebo in the conditions studied (very low quality evidence). Adverse event reporting was inconsistent an ...
... We could not pool data, but third tier evidence in individual studies indicated similar efficacy to other active interventions (gabapentin, morphine, chlorimipramine, and amitriptyline), and to placebo in the conditions studied (very low quality evidence). Adverse event reporting was inconsistent an ...
Toxicology and safety pharmacology and metabolic studies
... greatly in excess of proposed therapeutic dose - often dose for longer than intended human exposure Maximum tolerated dose (MTD): ‘High dose used in toxicity testing that is expected to produce limited toxicity when administered for the duration of the test period. It should not induce (a) overt tox ...
... greatly in excess of proposed therapeutic dose - often dose for longer than intended human exposure Maximum tolerated dose (MTD): ‘High dose used in toxicity testing that is expected to produce limited toxicity when administered for the duration of the test period. It should not induce (a) overt tox ...
LOMO 3-2014.indd
... disequilibrium of intestinal microbiome caused by the increase of pathogens.20-22 One of the requirements for the use of probiotics as adjuvants to remove urea or uremic toxins is the capacity of microorganisms to use metabolites as substrates. Thus, probiotics help intestinal microbiome decrease th ...
... disequilibrium of intestinal microbiome caused by the increase of pathogens.20-22 One of the requirements for the use of probiotics as adjuvants to remove urea or uremic toxins is the capacity of microorganisms to use metabolites as substrates. Thus, probiotics help intestinal microbiome decrease th ...
nerisone - GlaxoSmithKline
... shown to be teratogenic after dermal application in laboratory animals at doses similar to human therapeutic doses. There are no adequate and well controlled studies of NERISONE® in pregnant women. Administration of NERISONE® during pregnancy should only be considered if the expected benefit to the ...
... shown to be teratogenic after dermal application in laboratory animals at doses similar to human therapeutic doses. There are no adequate and well controlled studies of NERISONE® in pregnant women. Administration of NERISONE® during pregnancy should only be considered if the expected benefit to the ...
Pharmacotherapy in Psychiatry
... Atypical antipsychotics may be appropriate if Adverse effect is a particular concern Additional benefits for negative and cognitive symptoms required ...
... Atypical antipsychotics may be appropriate if Adverse effect is a particular concern Additional benefits for negative and cognitive symptoms required ...
Gout - RxFiles
... Colchicine or NSAIDs would be initial options for management of the acute attack.18,31,32 However, in a patient with contraindications or intolerance to these agents, a short course of corticosteroids might be a reasonable option.1-3,18,31,32,41 • Systemic steroids, oral or intramuscular, are suita ...
... Colchicine or NSAIDs would be initial options for management of the acute attack.18,31,32 However, in a patient with contraindications or intolerance to these agents, a short course of corticosteroids might be a reasonable option.1-3,18,31,32,41 • Systemic steroids, oral or intramuscular, are suita ...
NEUROLEPTICS
... Common onset 15-25 years of age 1% general population develops at some point in their lives Common major mental illness in 65+ years Smoking: 3 times more likely in schizophrenia than general population Excessive mortality 20% shorter life expectancy 10% suicide rate ...
... Common onset 15-25 years of age 1% general population develops at some point in their lives Common major mental illness in 65+ years Smoking: 3 times more likely in schizophrenia than general population Excessive mortality 20% shorter life expectancy 10% suicide rate ...
Antipsychotics - 2011
... negative symptoms may take several weeks. Symptoms often respond to antipsychotics in somewhat different time frames. Agitation, sleep and appetite often respond in the first 1-2 weeks whereas personal hygiene and basic interpersonal socialisation may be slower to respond (2-3 weeks), and psychotic ...
... negative symptoms may take several weeks. Symptoms often respond to antipsychotics in somewhat different time frames. Agitation, sleep and appetite often respond in the first 1-2 weeks whereas personal hygiene and basic interpersonal socialisation may be slower to respond (2-3 weeks), and psychotic ...
ADD-ADHD_Medication_..
... (can be reduced if medication taken with food), sedation (can be reduced by dosing in evening), lightheadedness. In adults: insomnia, sexual side effects, increased blood pressure. ...
... (can be reduced if medication taken with food), sedation (can be reduced by dosing in evening), lightheadedness. In adults: insomnia, sexual side effects, increased blood pressure. ...
full Prescribing Information
... There is an increased risk for hallucinations and psychosis in patients taking RYTARY. In a controlled clinical trial in patients with advanced Parkinson’s disease, 9/201 (4%) of RYTARYtreated patients reported hallucinations or psychosis compared to 2/192 (1%) of oral immediaterelease carbidopa-lev ...
... There is an increased risk for hallucinations and psychosis in patients taking RYTARY. In a controlled clinical trial in patients with advanced Parkinson’s disease, 9/201 (4%) of RYTARYtreated patients reported hallucinations or psychosis compared to 2/192 (1%) of oral immediaterelease carbidopa-lev ...
interferon alfa-2b - Cancer Care Ontario
... meperidine 50 mg IV or chlorpromazine 25-50 mg IM before dose. Tolerance to the flu-like syndrome develops over several months on continued dosing. The significance of developing neutralizing antibodies to interferon remains controversial. The incidence of antibody formation to interferon alpha ...
... meperidine 50 mg IV or chlorpromazine 25-50 mg IM before dose. Tolerance to the flu-like syndrome develops over several months on continued dosing. The significance of developing neutralizing antibodies to interferon remains controversial. The incidence of antibody formation to interferon alpha ...
Amiodarone Shared Care Guideline - Interface Pharmacist Network
... best avoided, but if co-prescribed, the maximum simvastatin dose should not exceed 20mg daily. Simprevir and sofosbuvir or sofosbuvir and daclatasvir or sofosbuvir and ledipasvir: Avoid concomitant use of amiodarone unless other antiarrhythmics cannot be given. The combination should only be used un ...
... best avoided, but if co-prescribed, the maximum simvastatin dose should not exceed 20mg daily. Simprevir and sofosbuvir or sofosbuvir and daclatasvir or sofosbuvir and ledipasvir: Avoid concomitant use of amiodarone unless other antiarrhythmics cannot be given. The combination should only be used un ...
Renagel (sevelamer hydrochloride)
... The possibility of an interaction cannot be excluded and close monitoring of blood concentrations of cyclosporin, mycophenolate mofetil and tacrolimus or dosing these medicines apart from RENAGEL to prevent GI binding (at least one hour before or three hours after RENAGEL) should be considered durin ...
... The possibility of an interaction cannot be excluded and close monitoring of blood concentrations of cyclosporin, mycophenolate mofetil and tacrolimus or dosing these medicines apart from RENAGEL to prevent GI binding (at least one hour before or three hours after RENAGEL) should be considered durin ...
Evaluation of H1-Antihistamine usage among dermatology
... overdose. [3] They may cause tachycardia, supraventricular arrhythmia, and prolongation of the QT interval in a dose-dependent manner. [4] Hydroxyzine, the most commonly used oral antihistaminic in our study does not induce ventricular arrhythmias, although changes in T waves have been reported when ...
... overdose. [3] They may cause tachycardia, supraventricular arrhythmia, and prolongation of the QT interval in a dose-dependent manner. [4] Hydroxyzine, the most commonly used oral antihistaminic in our study does not induce ventricular arrhythmias, although changes in T waves have been reported when ...
B-8 - New Psychiatric Medications
... • Starting dose 1 mg twice daily • Target dosage range 6-12 mg twice daily • Increase by no more than 2 mg twice daily every day until target range – Slow titration due to increased risk of low blood pressure, dizziness, and falls ...
... • Starting dose 1 mg twice daily • Target dosage range 6-12 mg twice daily • Increase by no more than 2 mg twice daily every day until target range – Slow titration due to increased risk of low blood pressure, dizziness, and falls ...
H2 Blockers
... can fail. Like we said in the case of hemorrhoidectomy, it gives immediate relief but not permanent solution because if risk factors still exist, this will give a chance for relapse. Some patients were obligated to do it several times, with the second time being more difficult because already there ...
... can fail. Like we said in the case of hemorrhoidectomy, it gives immediate relief but not permanent solution because if risk factors still exist, this will give a chance for relapse. Some patients were obligated to do it several times, with the second time being more difficult because already there ...
Novel Anti-platelet Agents and Anticoagulants
... Infarction 38). In this double blind, randomized controlled trial, 13,608 moderate to high risk patients with Acute Coronary Syndromes (ST-elevation myocardial infarction (STEMI), Non ST elevation Myocardial Infarction (N-STEMI) or unstable angina) scheduled for percutaneous coronary intervention (P ...
... Infarction 38). In this double blind, randomized controlled trial, 13,608 moderate to high risk patients with Acute Coronary Syndromes (ST-elevation myocardial infarction (STEMI), Non ST elevation Myocardial Infarction (N-STEMI) or unstable angina) scheduled for percutaneous coronary intervention (P ...
The Safety of COX
... Drug Safety and Risk Management Other speakers, SGEs 8 rheums, 19 physicians, 8 statisticians, 1 ethicist, patient and industry representatives ISSUES: 1. Does the agent pose a risk for CV events?; 2. Does the risk versus benefit profile of the drug support its marketing in the U.S.? 3. If continu ...
... Drug Safety and Risk Management Other speakers, SGEs 8 rheums, 19 physicians, 8 statisticians, 1 ethicist, patient and industry representatives ISSUES: 1. Does the agent pose a risk for CV events?; 2. Does the risk versus benefit profile of the drug support its marketing in the U.S.? 3. If continu ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.